Trexquant Investment’s Design Therapeutics DSGN Stock Holding History

Trexquant Investment’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$407K	Sell	28,150 -88,961	-76%	-$1.11M	﹤0.01%	1689
2026 Q1	$1.25M	Buy	117,111 +17,144	+17%	+$173K	0.01%	1155
2025 Q4	$938K	Buy	+99,967	New	+$783K	0.01%	1202
2023 Q3	–	Sell	-46,524	Closed	-$293K	–	1540
2023 Q2	$293K	Sell	46,524 -4,315	-8%	-$26.4K	0.01%	1204
2023 Q1	$293K	Buy	+50,839	New	+$380K	0.01%	1212
2022 Q4	–	Sell	-11,296	Closed	-$189K	–	1442
2022 Q3	$189K	Buy	+11,296	New	+$225K	0.01%	1204

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trexquant Investment's DSGN Position: Q2 2026 in Review

Trexquant Investment reduced its Design Therapeutics (DSGN) stake by 76% in Q2 2026, selling an estimated $1.11M and leaving 28,150 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #1689.

Trexquant Investment first reported a position in DSGN in Q3 2022 and has held it in 6 quarters since. The position peaked at $1.25M in Q1 2026. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Trexquant Investment held 28,150 shares of Design Therapeutics worth $407K as of Q2 2026.
Trexquant Investment sold 88,961 Design Therapeutics shares in Q2 2026, an estimated $1.11M.
Design Therapeutics made up ﹤0.01% of Trexquant Investment's portfolio in Q2 2026, its #1689 holding.
Trexquant Investment first reported a position in Design Therapeutics in Q3 2022 and has held it in 6 quarters since.
Trexquant Investment's Design Therapeutics position peaked at $1.25M in Q1 2026.
136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.